rs2069526 — CYP1A2 -739T>G

CYP1A2 -739T>G — A Secondary Intronic Variant in the Caffeine-Metabolizing Gene

CYP1A2 is the liver enzyme responsible for breaking down roughly 95% of caffeine, as well as several important medications including clozapine, theophylline, and escitalopram. The enzyme's activity varies substantially between individuals — up to 40-fold — driven by a combination of genetic polymorphisms, smoking status, and dietary factors. The rs2069526 variant (-739T>G) is an intronic change located near the 5' end of CYP1A2 ¹¹ HGVS: NM_000761.5:c.-10+103T>G; chromosome 15, GRCh38 position 74,748,999. Its G allele is rare globally (approximately 5–7%) and has been associated with differences in how certain CYP1A2 substrates are cleared, though its independent functional effect remains less clearly established than the better-studied rs762551 (*1F) variant.

The Mechanism

As an intronic variant, rs2069526 does not alter the amino acid sequence of the CYP1A2 protein. Instead, it may influence ²² gene expression: how much of the enzyme protein is made in liver cells or splicing efficiency. Intronic variants near exon-intron boundaries or regulatory regions can create or disrupt binding sites for splicing factors or transcription regulators. The -739 position places this variant upstream of the main coding region, where it could modulate basal or inducible transcription in conjunction with other haplotype-defining SNPs.

The Evidence

A pharmacogenomics study of 158 Taiwanese patients receiving escitalopram³³ pharmacogenomics study of 158 Taiwanese patients receiving escitalopram
Kuo HW et al. CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics, 2013 found that rs2069526 was significantly associated with the S-DDCIT/S-DCIT metabolic ratio at week 2 (p = 0.018). Individuals with G alleles — which correlated with elevated metabolic ratios — experienced more pronounced adverse effects early in treatment. Notably, CYP2C19 is the primary pathway for escitalopram; this finding suggests rs2069526 may tag a CYP1A2 haplotype that modulates a secondary metabolic route or reflects linkage disequilibrium with a functionally important variant.

A meta-analysis of lung cancer risk⁴⁴ meta-analysis of lung cancer risk
Bu ZB et al. Four polymorphisms in CYP1A2 and lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 2014 pooled five studies (657 cases, 984 controls) and found no significant association between rs2069526 and lung cancer risk. A Swedish-Korean comparison study⁵⁵ Swedish-Korean comparison study
Ghotbi R et al. CYP1A2 genetic polymorphisms, enzyme activity and genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol, 2007 found no significant genotype-phenotype relationship for the -739T>G variant alone, while confirming that the related rs762551 (*1F) allele was associated with higher enzyme inducibility in smokers. Together, the evidence suggests rs2069526 may have limited independent functional significance but could be part of a haplotype block tagging broader CYP1A2 activity differences.

Practical Actions

Because this variant is in the same gene as the well-characterized rs762551 (*1F), individuals carrying the G allele at rs2069526 should be aware that CYP1A2 activity in their case remains less predictable from this single variant alone. For medications processed primarily by CYP1A2 — particularly clozapine, theophylline, and tizanidine — therapeutic drug monitoring is the most reliable approach rather than genotype-directed dosing from this marker alone. Smoking is the dominant environmental regulator of CYP1A2 and can increase enzyme activity by two- to three-fold, outweighing most genetic effects; changes in smoking status during CYP1A2-substrate treatment require dose re-evaluation.

Interactions

rs2069526 was found to be significantly associated with escitalopram metabolic ratios in the same study that identified rs2069521 and rs4646425 (Kuo et al., 2013). These variants may act in concert as a haplotype, meaning the observed escitalopram association may reflect combined haplotype effects rather than the action of rs2069526 in isolation. The rs762551 (*1F) variant at the same locus has substantially stronger and better-replicated evidence for affecting CYP1A2 inducibility, caffeine clearance, and cardiovascular risk from coffee.